Drug Profile
Pomisartan
Alternative Names: BIBR 363Latest Information Update: 14 Jun 2001
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antihypertensives; Heart failure therapies; Neuroprotectants
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 14 Jun 2001 No-Development-Reported for Congestive heart failure in Germany (PO)
- 14 Jun 2001 No-Development-Reported for Hypertension in Germany (PO)
- 19 Aug 1997 Investigation in Congestive heart failure in Germany (PO)